Study guide
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting
NCRA Oncology Data Specialist ODS-C
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The ODS-C Exam, the Oncology Data Specialist Profession & Standard Setters
1.1 ODS Exam Structure, Timing, Scoring & 2026 Testing Windows 1.2 From CTR to ODS: The Credential, Eligibility Routes & the Registrar's Role 1.3 Standard-Setting Organizations & the Manuals They Publish
2 Chapter 2: Legal Framework, HIPAA & State Reporting Laws
2.1 HIPAA Privacy Rule & the Public Health Reporting Exception 2.2 HIPAA Security Rule, Safeguards & Breach Notification 2.3 State Mandatory Cancer Reporting Laws & Statutory Authority
3 Chapter 3: Confidentiality, Release of Information, Ethics & Credential Maintenance
3.1 Patient Confidentiality Protocols & Data Access Policies 3.2 Handling Subpoenas, Discovery & Registry Immunity Statutes 3.3 NCRA Code of Ethics & ODS Credential Maintenance
4 Chapter 4: Registry Organization, Staffing & Information Systems
4.1 Types of Cancer Registries, Their Functions & Registry Operating Protocols 4.2 Registry Staffing Formulas, Time Studies & Resource Allocation 4.3 Electronic Registry Systems, Security & Disaster Recovery Planning
5 Chapter 5: Cancer Committee, Cancer Conferences & Quality Improvement
5.1 The Cancer Committee: CoC Standards 2.1–2.4, the CLP & Annual Program Activities 5.2 Multidisciplinary Cancer Case Conferences (CoC Standard 2.5) 5.3 Quality Improvement Principles & CoC Chapter 7 (Standards 7.1–7.3)
6 Chapter 6: CoC Accreditation Standards, NCDB & Data Quality
6.1 CoC Accreditation: Standards Structure, Program Categories & Accreditation Awards 6.2 The National Cancer Database (NCDB), RCRS Submission & CoC Quality Measures 6.3 Quality Control Plans & Audit Techniques (CoC Standard 6.1)
7 Chapter 7: Surveillance Programs, NAACCR Standards, Epidemiology & Statistics
7.1 National Cancer Surveillance Programs: SEER & CDC NPCR 7.2 NAACCR Data Exchange Standards, XML Data Specifications & Registry Certification 7.3 Basic Cancer Epidemiology & Descriptive Statistics 7.4 Basic Statistics: Frequency Distributions, Central Tendency, Risk Ratios & Odds Ratios 7.5 Survival Analysis, Life Tables & Presentation of Registry Data
8 Chapter 8: Medical Terminology, Anatomy & Types of Cancer
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting 8.2 Human Anatomy & Physiology for Registrars: Tissues, Organ Walls, Subsites & Lymphatic Drainage 8.3 Types & Characteristics of Cancer: Benign vs. Malignant, Tumor Families, Spread & Precursors
9 Chapter 9: Casefinding & Reportability
9.1 Principles of Casefinding & Facility Reference Dates 9.2 Casefinding Sources: Pathology, Cytology, Disease Index & Logs 9.3 Reportability: What CoC, SEER and NPCR Require, Including Non-Malignant CNS Tumors 9.4 Ambiguous Terminology: Reportable Terms, Cytology, Discrepancies & "References of Last Resort"
10 Chapter 10: Diagnostic Procedures, Pathology Reporting, Lab Methods & Prognostic Indicators
10.1 Diagnostic & Staging Procedures: Imaging, Endoscopy, Biopsy & How They Are Coded 10.2 Pathology Reporting, CAP Cancer Protocols & Electronic Pathology (CoC Standard 5.1) 10.3 Specialty Laboratory Testing Methods: IHC, FISH, PCR/RT-PCR, NGS, Flow Cytometry & Cytogenetics 10.4 Prognostic Indicators & Site-Specific Data Items (SSDIs): HPV, KRAS, HER2 and More
11 Chapter 11: Class of Case, Key Dates & Case Identifiers
11.1 Class of Case, Date of First Contact, Date of Diagnosis & Accession/Sequence Numbers 11.2 Analytic Classes of Case (00, 10–14, 20–22): Definitions & Decision Rules 11.3 Nonanalytic Classes of Case (30–49, 99) & Why Central Registries Need Them
12 Chapter 12: Follow-Up, Vital Status & Recurrence
12.1 Follow-Up Purpose, Active & Passive Methods, and Follow-Up Source Codes 12.2 CoC Standard 6.5 Follow-Up Rates: Windows, Exclusions & Calculations 12.3 Vital Status, Date of Last Contact, Cancer Status & Death Clearance 12.4 Recurrence: Type of First Recurrence [1880], Date of First Recurrence [1860] & Recurrence vs. New Primary
13 Chapter 13: Abstracting, ICD-O-3.2 Site & Histology Coding, and Grade
13.1 The Abstracting Process: Workflow, Source Documents, Timeliness & Text Documentation 13.2 ICD-O-3.2 Topography, Primary Site Rules & Laterality 13.3 ICD-O-3.2 Morphology: Histology, Behavior & the Solid Tumor Histology Rules 13.4 Grade: The Four Time-Specific Grade Items & Site-Specific Grade Tables
14 Chapter 14: Solid Tumor Rules & Hematopoietic Coding Rules
14.1 Solid Tumor Rules: Purpose, Site Groups, Navigation & Timing Principles 14.2 Solid Tumor Rules for Breast, Colon/Rectum & Lung: The Multiple Primary Rules in Order 14.3 Solid Tumor Rules for Head & Neck, Kidney, Urinary, CNS, Melanoma & Other Sites 14.4 Hematopoietic & Lymphoid Neoplasms: Heme Manual, Heme DB, Multiple Primary & Primary Site Rules
15 Chapter 15: Staging: AJCC TNM (8th Edition & Version 9 Lung) and Summary Stage 2018
15.1 AJCC TNM Principles: Categories, Prefixes, Suffixes, General Rules & Registry Items 15.2 AJCC Time Frames: Clinical, Pathological, Post-Therapy (yc, yp), Recurrence & Autopsy 15.3 Breast Staging (AJCC 8th Edition, Part XI): T, N, M, Anatomic & Prognostic Stage Groups 15.4 Lung Staging (AJCC Version 9, 2025+): T, N2a/N2b, M1c1/M1c2 & New Stage Groups 15.5 Male Genital & Urinary Tract Staging (AJCC 8th Parts XIII–XIV): Prostate, Testis, Kidney, Bladder, Renal Pelvis & Ureter 15.6 SEER Summary Stage 2018: Codes, Timing, General Rules & Site Examples
16 Chapter 16: First-Course Treatment Coding (STORE 2025) & EDITS
16.1 Treatment Types, First Course of Treatment & Evidence-Based Guidelines (NCCN) 16.2 Surgery Coding: Rx Summ–Surg 2023 [1291], Lymph Node Surgery [1292], Other Site [1294], Margins & Reason for No Surgery 16.3 Radiation, Systemic, Transplant, Other & Palliative Treatment Coding (STORE 2025) 16.4 NAACCR EDITS, Over-ride Flags & Data Validation
8.1 Medical Terminology & Standard Abbreviations for Cancer Abstracting
Key Takeaways Explain This Topic AI
Most oncology terms are built from a root plus a prefix or suffix: adeno- (gland) + carcin (epithelial cancer) + -oma (tumor) = adenocarcinoma, a malignant tumor of glandular epithelium.
The suffix -sarcoma marks a malignant tumor of connective tissue (osteo-, chondro-, lipo-, leiomyo-, rhabdomyo-), while -blastoma usually marks an embryonal tumor of immature cells.
Surgical suffixes differ: -ectomy removes, -otomy cuts into, -ostomy creates an opening, and -scopy views with an instrument.
Abbreviations such as "r/o" (rule out) and "c/w" (consistent with) reverse the meaning of a diagnostic statement for reportability, so always expand abbreviations before applying ambiguous-term rules.
Registry text fields should use only standard abbreviations from the registry's approved list, because other readers (central registries, auditors) must interpret the text without the source record.
Last updated: September 2026
Why terminology is tested
"Medical terminology and standard abbreviations" is a Domain 3 topic, and it underlies every other data identification skill. A registrar who cannot read "s/p TAH-BSO, peritoneal washings neg, omentum w/ microscopic mets" quickly and correctly cannot stage an ovarian cancer. Terminology questions are usually embedded in case scenarios rather than asked as definitions.
Building terms from parts
Medical terms combine a root (the core meaning), often a prefix (at the start) and a suffix (at the end), with a combining vowel (usually "o") between parts.
Tissue-of-origin roots and prefixes
- Word part Meaning Example
- adeno- gland adenocarcinoma, adenoma
- angio-, hemangio- vessel, blood vessel angiosarcoma, hemangioma
- carcin- cancer of epithelium carcinoma, carcinogen
- chondro- cartilage chondrosarcoma
- cyst- sac, bladder cystoscopy, cystadenocarcinoma
- hepato- liver hepatocellular carcinoma
- leiomyo- smooth muscle leiomyosarcoma
- rhabdomyo- skeletal (striated) muscle rhabdomyosarcoma
- lipo- fat liposarcoma
- lympho- lymph, lymphocyte lymphoma, lymphadenopathy
- melano- black, pigment melanoma
- meningio- meninges meningioma
- myelo- bone marrow (or spinal cord) myeloma, myelodysplastic
- neuro- nerve neuroblastoma, neuroendocrine
- osteo- bone osteosarcoma
- squam- scale-like squamous cell carcinoma
- Suffixes
- Suffix Meaning Example
- oma tumor or mass (not always malignant) lipoma (benign), carcinoma (malignant)
- sarcoma malignant tumor of connective tissue osteosarcoma
- blastoma tumor of immature (embryonal) cells nephroblastoma (Wilms), retinoblastoma
-plasia formation or growth hyperplasia (more cells), dysplasia (disordered growth), metaplasia (one cell type replaced by another), anaplasia (loss of differentiation), neoplasia (new, autonomous growth)
- ectomy surgical removal mastectomy, lobectomy, colectomy
- otomy cutting into laparotomy, thoracotomy
- ostomy surgically created opening colostomy, ileostomy
- scopy visual examination with an instrument colonoscopy, bronchoscopy
- penia deficiency neutropenia, pancytopenia
- emia blood condition leukemia, anemia
- megaly enlargement splenomegaly, hepatomegaly
Watch the traps: "-oma" is not always malignant (lipoma, adenoma, meningioma), and "lymphoma" and "melanoma" are malignant even though they end in "-oma."
Directional and descriptive terms
Anterior/posterior, superior/inferior, medial/lateral, proximal/distal, superficial/deep.
Ipsilateral means on the same side, contralateral the opposite side, and bilateral both sides. These matter for laterality coding and for deciding whether nodes are regional or distant (for example, contralateral axillary nodes in breast cancer are distant).
Paired organs have right and left sides. The registry must record Laterality [410] : 0 = not a paired site; 1 = right; 2 = left; 3 = only one side involved, origin not specified; 4 = bilateral involvement, origin unknown, single primary; 5 = paired site, midline tumor; 9 = paired site, laterality unknown.
Pathology vocabulary
Term Meaning for the registrar
In situ / intraepithelial / noninvasive Malignant cells that have not crossed the basement membrane (behavior /2)
- Invasive / infiltrating Malignant cells that have crossed the basement membrane (behavior /3)
- Microinvasion Invasion of 1 mm or less (for example, breast T1mi)
Differentiation How much the tumor resembles normal tissue: well, moderately or poorly differentiated, or undifferentiated
- LVI Lymphovascular invasion (tumor in lymphatic or vascular spaces)
- PNI Perineural invasion
- ENE Extranodal extension (tumor beyond the lymph node capsule)
- Margin The cut edge of the specimen; "positive" means tumor at the ink
- Satellite / tumor deposit A discontinuous tumor nodule near the primary or in the drainage field
- High-yield abbreviations
Area Abbreviations
Procedures FNA (fine-needle aspiration), bx (biopsy), SLNB (sentinel lymph node biopsy), ALND (axillary lymph node dissection), BCS (breast-conserving surgery), MRM (modified radical mastectomy), WLE (wide local excision), TURBT (transurethral resection of bladder tumor), TURP (transurethral resection of prostate), TAH-BSO (total abdominal hysterectomy with bilateral salpingo-oophorectomy), LAR (low anterior resection), APR (abdominoperineal resection), EGD, ERCP, EUS (endoscopic ultrasound), EBUS (endobronchial ultrasound), VATS (video-assisted thoracoscopic surgery)
- Imaging CXR, CT, MRI, PET or PET/CT, US (ultrasound), BI-RADS, PI-RADS, LI-RADS
- Lab and markers CBC, WBC, CEA, PSA, AFP, beta-hCG, LDH, CA-125, CA 19-9
- Pathology and biomarkers IHC (immunohistochemistry), FISH, NGS, ER/PR/HER2, MSI, MMR, PD-L1, Ki-67
Treatment XRT or RT (radiation), EBRT, IMRT, SBRT, SRS, HDR/LDR brachytherapy, ADT (androgen deprivation therapy), BCG (intravesical immunotherapy)
Clinical shorthand Dx, Tx, Hx, Sx, s/p (status post), h/o (history of), r/o (rule out) , c/w (consistent with) , NED (no evidence of disease), AWD (alive with disease), ECOG, KPS (performance status)
Abbreviations that change reportability
"R/o carcinoma" means rule out . It is not diagnostic and is not on the reportable ambiguous-terms list.
"C/w carcinoma" means consistent with . It is a reportable ambiguous term (see Section 9.4).
"Hx of breast CA" describes a history , not a new diagnosis. Decide whether the disease is active or history only before you assign a Class of Case.
Safe abbreviation practice
Expand any unfamiliar or ambiguous abbreviation before you code. "PE" can mean physical exam or pulmonary embolism, and "MS" can mean multiple sclerosis or morphine sulfate.
Use only approved abbreviations in registry text fields. Central registries, auditors and future abstractors must understand the text without the source record.
Follow the Joint Commission "Do Not Use" principle for clinical orders. In registry text, the same rule means never writing an abbreviation that someone could reasonably misread.
- Practice: decode a pathology line
- "LUL wedge bx: poorly diff adenoCA, c/w lung primary (TTF-1+, CK7+, CK20−); LVI present; margins neg; 0/3 LN."
LUL = left upper lobe (C34.1); Laterality = 2 (left).
"Poorly diff adenoCA" = poorly differentiated adenocarcinoma (8140/3; grade recorded according to the Grade Manual).
"C/w lung primary" = consistent with a lung primary, supported by the IHC profile (TTF-1 and CK7 positive, CK20 negative).
LVI present; negative margins; zero of three lymph nodes positive.